|
|
The current role of TZD’s in diabetes & CV risk
|
|
|
|
Use of Pioglitazone
|
|
|
|
TZDs are activators of PPAR gamma?
|
|
|
|
Patho-physiology of Type 2 diabetes
|
|
|
|
Pioglitazone + existing therapy
|
|
|
|
Time to Primary Composite Endpoint*
|
|
|
|
PROactive Total Events
|
|
|
|
Time to : Death, MI ( excluding silent ) or Stroke
|
|
|
|
Time to Fatal/Non-fatal MI
|
|
|
|
Time to Fatal or Non-Fatal Stroke
|
|
|
|
|
|
CHICAGO:Glycaemic Control Change in HbA1c
|
|
|
|
CHICAGO: Treatment effect on posterior wall mean CIMT
|
|
|
|
PERISCOPE IVUS Trial Primary Endpoint
|
|
|
|
PERISCOPE: Comparison to Other Trials
|
|
|
|
Benefits of Pioglitazone: Lipid Metabolism
|
|
|
|
PROactive Metabolic Effects of Pioglitazone
|
|
|
|
|
|
|
|
Burden in T2DM: Events in Controlled Clinical Studies
|
|
|
|
Bladder Cancer: Clinical Trials
|
|
|
|
Bladder Cancer: Epidemiological Studies
|
|
|
|
KPNC 3rd Interim Analysis
|
|
|
|
CNAMTS Overall Results
|
|
|
|
Overall Malignancies
|
|
|
|
Bladder Cancer Conclusions
|
|
|
|
Slide 28
|
|
|
|
European Medicines Agency
|
|
|
|
European Medicines Agency
|
|
CDMC prof betteridge (PDF 3.2MB)
Share this page with your colleagues and friends: